Anirvan Ghosh, Unity CEO (Biogen via Facebook)
Unity touts PhII win, plots head-to-head with Regeneron drug in 'defining moment'
Unity Biotechnology is ready to go head-to-head against Regeneron’s blockbuster eye drug Eylea.
The biotech, which has been working for years to prove that it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
